Many patients with cancer suffer from anemia, depression, and an impaired quality of life
(QoL). These patients often also show decreased plasma tryptophan levels and increased …

Over the last decade, tryptophan catabolism has been firmly established as a powerful
mechanism of innate and adaptive immune tolerance. The catabolism of tryptophan is a …

Cancer‐related fatigue (CRF) is a common complication of cancer and its treatment that can
significantly impair quality of life. Although the specific mechanisms remain poorly …

Highlights•Tryptophan follows three metabolic fates: incorporation into proteins, production
of indoles, and breakdown into kynurenine.•IDO1 is an endogenous mechanism of …

Tryptophan catabolism by indoleamine 2, 3-dioxygenase (IDO) alters inflammation and
favors T-cell tolerance in cancer, but the underlying molecular mechanisms remain poorly …

Tryptophan catabolism in cancer is increasingly being recognized as an important
microenvironmental factor that suppresses antitumor immune responses. It has been …

Colorectal cancer (CRC) is the third most common cancer worldwide and the second
leading cause of cancer death in the United States. Cytotoxic therapies cause significant …

1-methyl-D-tryptophan (1-D-MT) is currently being used in clinical trials in patients with
relapsed or refractory solid tumors with the aim of inhibiting indoleamine-2, 3-dioxygenase …

Blockade of the immunosuppressive tryptophan catabolism mediated by indoleamine 2, 3-
dioxygenase 1 (IDO1) and tryptophan 2, 3-dioxygenase (TDO) holds enormous promise for …

Background: Indoleamine (2, 3)-dioxygenase (IDO) catalyses the initial, rate-limiting step in
the degradation of the essential amino acid tryptophan. Via tryptophan deprivation, IDO …